Clinical Trials
2 trialsNCT04523402 2020-08-21
Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis
Eastern Hepatobiliary Surgery Hospital
Phase 2 Unknown
NCT04506281 2020-08-10
PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Shanghai Zhongshan Hospital
Phase 2 Unknown